E Li

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.